NCT06071429View on ClinicalTrials.gov

Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2032

Conditions
Chronic Limb-Threatening Ischemia
Interventions
DEVICE

MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold

CLTI patients treated with MAGNITUDE BRS

DEVICE

Percutaneous Transluminal Angioplasty (PTA)

CLTI patients treated with PTA

Trial Locations (2)

10016

RECRUITING

NYU Langone Health, New York

10032

NOT_YET_RECRUITING

CUMC/NYP, New York

All Listed Sponsors
lead

R3 Vascular Inc.

INDUSTRY